Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This review evaluates the evidence for prophylactic haemostasis during endobronchial biopsy, centered on the PROTECT trial results, while integrating contemporary data on procedural safety, pre-procedural screening, and technical optimizati
This article analyzes the long-term follow-up data from the FIBRONEER-IPF trial, evaluating the efficacy of nerandomilast in idiopathic pulmonary fibrosis. While the drug reduces FVC decline, its impact on composite clinical outcomes remain
The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional a
A landmark study identifies a decade-long conserved sequence of disease progression in IPF, revealing that DLCO decline precedes FVC impairment by years, providing a new framework for early diagnosis and clinical trial design.
A large-scale longitudinal study reveals that obesity and diabetes synergistically amplify the risk of advanced liver disease in individuals with Alpha-1 Antitrypsin Deficiency (AATD), while also identifying a complex relationship between b
This study identifies the transition of cardiac fibroblasts to myofibroblasts as a critical driver of right ventricular failure in PAH, highlighting the role of UCP2 deficiency and the rs659366 SNP as key clinical indicators of decompensati
This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin
This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards
A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
The Phase 3 ASTRUM-002 trial demonstrates that adding serplulimab to chemotherapy significantly extends progression-free survival in non-squamous NSCLC, though the further addition of a bevacizumab biosimilar (HLX04) did not provide statist
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
The Phase 3 ARTS trial demonstrates that adjuvant aumolertinib significantly improves disease-free survival in patients with resected stage II-IIIB EGFR-mutated NSCLC, reducing the risk of recurrence or death by 83% compared to placebo, wit
A multicentre prospective study reveals that infants developing moderate-to-severe BPD exhibit significant lung aeration and gas exchange deficits as early as day 10, with a critical pathophysiological peak at 26 days of life, regardless of
An Italian multicentric study reveals that while ETI therapy significantly improves several health markers in Cystic Fibrosis patients, its impact on peak aerobic capacity is modest, emphasizing the indispensable need for structured physica
Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchi
A large-scale multicenter study reveals that adherence to lymph node dissection guidelines significantly improves survival in early-stage lung adenocarcinoma patients with high-grade histologic patterns, while offering no significant benefi
The CORAL Phase 2b trial demonstrates that oral nalbuphine extended release significantly reduces objective cough frequency and improves patient-reported symptoms in idiopathic pulmonary fibrosis, addressing a critical unmet need for managi
A multicentre feasibility trial demonstrates that Singing for Lung Health (SLH) is a viable follow-up to pulmonary rehabilitation, showing high retention rates and strong participant enthusiasm for a definitive randomized controlled trial.
The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para
Open language-specific specialty feeds and department pages.